Highlights Newsletter 2
This newsletter presents you the best read sessions:
1. Taletrectinib for patients with ROS1+ non-small cell lung cancer: the global TRUST-II study
3. Selpercatinib efficacy from the LIBRETTO-001 and LIBRETTO-431 trials
4. Association between short-term cumulative exposure to PM2.5 and lung cancer